Mirum Pharmaceuticals Inc Stock News

FOSTER CITY, Calif.--(BUSINESS WIRE)---- $MIRM #leadership--Mirum Pharmaceuticals Appoints Doug Sheehy, JD as Chief Legal Officer.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: 3rd Annual H.C. Wainwright BioConnect Investor Conference ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

FOSTER CITY, Calif.--(BUSINESS WIRE)---- $mirm #easl2025--Volixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Andrew McKibben - SVP, Strategic Finance and IR Chris Peetz - CEO Peter Radovich - President and COO Eric Bjerkholt - CFO Conference Call Participants Gavin Clark-Gartner - Evercore Jessica Fye - JPMorgan Selena Zhang - Morgan Stanley Ryan McElroy - Leerink Partners David Lebo...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update.

Mirum Pharmaceuticals boasts a strong portfolio with LIVMARLI, Ctexli, and Cholbam, as well as two promising pipeline candidates --volixibat and MRM-3379-- both of which carry billion-dollar potential. The company is expected to be cash flow positive by the end of FY 2025, with significant revenue growth projected for 2025 and 2026. Upcoming data presentations and earnings could drive the stock...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025.